Art

J-GLOBAL ID：202202271688767438   Reference number：22A1023605

A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants

SARS-CoV-2変異体に対する強力で保護的なヒト中和抗体【JST・京大機械翻訳】

Author (26)： Shan Sisi (1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China) ,  Mok Chee Keng (2Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore) ,  Mok Chee Keng (3Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore) ,  Zhang Shuyuan (4The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University, Beijing, China) ,  Lan Jun (4The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University, Beijing, China) ,  Li Jizhou (5School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China) ,  Yang Ziqing (1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China) ,  Wang Ruoke (1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China) ,  Cheng Lin (6Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China) ,  Fang Mengqi (1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China) ,  Aw Zhen Qin (2Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore) ,  Aw Zhen Qin (3Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore) ,  Aw Zhen Qin (7Infectious Disease Translation Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore) ,  Yu Jinfang (4The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University, Beijing, China) ,  Zhang Qi (1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China) ,  Shi Xuanling (1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China) ,  Zhang Tong (8Beijing Youan Hospital, Capital Medical University, Beijing, China) ,  Zhang Zheng (6Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China) ,  Wang Jianbin (5School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China) ,  Wang Xinquan (4The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University, Beijing, China) ,  Chu Justin Jang Hann (2Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore) ,  Chu Justin Jang Hann (3Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore) ,  Chu Justin Jang Hann (7Infectious Disease Translation Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore) ,  Zhang Linqi (1NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Disease Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China) ,  Zhang Linqi (9Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, China) ,  Zhang Linqi (10Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen, China)
Material： Frontiers in Immunology (Web)
Volume： 12  Page： 766821  Publication year： 2021 
JST Material Number： U7074A  ISSN： 1664-3224  Document type： Article
Article type： 原著論文  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： As severe acute respiratory sy...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=22A1023605&from=J-GLOBAL&jstjournalNo=U7074A") }}

Thesaurus term： low temperature ,  *antibody ,  death ,  receptor ,  *mutant ,  human(primates) ,  *variation(biology) ,  vaccine ,  binding site ,  epitope ,  monoclonal antibody ,  targeting ,  *neutralization ,  *neutralizing antibody
Semi thesaurus term： *重症急性呼吸器症候群 , 【Automatic Indexing@JST】

Author keywords (5)： SARS-CoV-2 ,  variants of concern ,  human neutralizing antibody ,  in vivo protection ,  epitope

JST classification (2)： Biochemistry of antigens,antibodies,complements  (ED04020L) ,  Virus biochemistry  (EG04030F)

Reference (58)：

• Fujino T, Nomoto H, Kutsuna S, Ujiie M, Suzuki T, Sato R, et al. Novel SARS-CoV-2 Variant in Travelers From Brazil to Japan. Emerg Infect Dis (2021) 27(4):1243-5. doi: doi: 10.3201/eid2704.210138
• Kupferschmidt K. Fast-Spreading U.K. Virus Variant Raises Alarms. Science (2021) 371(6524):9-10. doi: doi: 10.1126/science.371.6524.9
• Maggi F, Novazzi F, Genoni A, Baj A, Spezia PG, Focosi D, et al. Imported SARS-CoV-2 Variant P.1 in Traveler Returning From Brazil to Italy. Emerg Infect Dis (2021) 27(4):1249-51. doi: doi: 10.3201/eid2704.210183
• Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a SARS-CoV-2 Variant of Concern in South Africa. Nature (2021) 592(7854):438-43. doi: doi: 10.1038/s41586-021-03402-9
• Tegally H, Wilkinson E, Lessells RJ, Giandhari J, Pillay S, Msomi N, et al. Sixteen Novel Lineages of SARS-CoV-2 in South Africa. Nat Med (2021) 27(3):440-6. doi: doi: 10.1038/s41591-021-01255-3

Terms in the title (4)： SARS-CoV-2 ,  変異体 ,  ヒト ,  中和抗体